Evogene (EVGN) Receivables (2012 - 2025)
Evogene (EVGN) posted Receivables of $1.9 million for Q4 2025, down 5.57% sequentially from $2.0 million in Q3 2025, and down 40.35% YoY from $3.2 million in Q4 2024.
Evogene (EVGN) Receivables (2012 - 2025) Analysis & Trends
Evogene has reported Receivables for 14 years, with the latest figure at $1.9 million in Q4 2025.
- Quarterly Receivables fell 40.35% year-over-year to $1.9 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $1.9 million (down 40.35% YoY) and the FY2025 annual result came in at $1.9 million, down 40.35% from the prior year.
- Receivables eased to $1.9 million in Q4 2025 per EVGN's latest filing, from $2.0 million in the prior quarter.
- Over five years, Receivables peaked at $4.1 million in Q2 2024 and troughed at $1.6 million in Q2 2023.
- A 5-year average of $2.7 million and a median of $2.7 million in 2021 frame the typical range for Receivables.
- The sharpest annual moves came in 2024 and 2025: Receivables soared 154.98% in 2024, then plunged 56.04% in 2025.
- Over 5 years, Receivables stood at $2.9 million in 2021, then plunged by 37.59% to $1.8 million in 2022, then soared by 81.97% to $3.3 million in 2023, then fell by 5.26% to $3.2 million in 2024, then sank by 40.35% to $1.9 million in 2025.
- According to Business Quant data, Receivables over the past three periods registered $1.9 million, $2.0 million, and $1.8 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 2.13 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 6.57 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.93 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 160.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 1.06 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 912.74 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 1.09 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 215.33 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Evogene | 4.38 Mn | 4.38 Mn | 204,000.00 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 1.88 Mn |
| Sep 30, 2025 | 1.99 Mn |
| Jun 30, 2025 | 1.79 Mn |
| Mar 31, 2025 | 3.29 Mn |
| Dec 31, 2024 | 3.16 Mn |
| Sep 30, 2024 | 3.95 Mn |
| Jun 30, 2024 | 4.07 Mn |
| Mar 31, 2024 | 3.69 Mn |
| Dec 31, 2023 | 3.33 Mn |
| Sep 30, 2023 | 3.22 Mn |
| Jun 30, 2023 | 1.60 Mn |
| Mar 31, 2023 | 2.02 Mn |
| Dec 31, 2022 | 1.83 Mn |
| Sep 30, 2022 | 2.66 Mn |
| Jun 30, 2022 | 2.29 Mn |
| Mar 31, 2022 | 2.90 Mn |
| Dec 31, 2021 | 2.93 Mn |
| Sep 30, 2021 | 2.01 Mn |
| Jun 30, 2021 | 2.50 Mn |
| Mar 31, 2021 | 2.80 Mn |